• APRIL 16, 2014
    • 0

    Jakafi Prolongs Survival in Primary Myelofibrosis

    By tstorla Jakafi® (ruxolitinib) prolongs survival in patients with intermediate- or high-risk primary myelofibrosis compared with patients who receive conventional therapy, according to the results of a study published in the journal Blood. Primary myelofibrosis is a type of blood cancer known as a myeloproliferative neoplasm. It involves the abnormal development and function of bone

    Read more
    • APRIL 9, 2014
    • 0

    Avastin Plus Chemotherapy Improves Progression-Free Survival in Platinum-Resistant Recurrent Ovarian Cancer

    By tstorla The addition of Avastin® (bevacizumab) to standard chemotherapy significantly improved progression-free survival and objective response rate among women with platinum-resistant recurrent ovarian cancer, according to the results of a study published early online in the Journal of Clinical Oncology. Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer

    Read more
    • APRIL 8, 2014
    • 0

    Post-Mastectomy Radiation Beneficial for Cancer That Has Spread to Only a Few Lymph Nodes

    By tstorla Women whose breast cancer has spread to just a few lymph nodes are less likely to experience recurrence or die from their disease if they undergo radiation therapy after mastectomy, according to the results of a study published in The Lancet. Post-mastectomy radiation has been shown to reduce the risk of recurrence and

    Read more
    • APRIL 2, 2014
    • 0

    Updated Guidelines for Sentinel Node Biopsy in Early Stage Breast Cancer

    By tstorla The American Society of Clinical Oncology (ASCO) has issued new recommendations for the use of sentinel lymph node biopsy in patients with early stage breast cancer. The guidelines were published online in the Journal of Clinical Oncology. For women with early breast cancer, determining whether the cancer has spread to the axillary (under

    Read more